T1	p 90 121	healthy adults ?60 years of age
T2	p 512 538	210 subjects ?60 years old
T3	i 72 86	zoster vaccine
T4	i 326 347	zoster vaccine ( ZV )
T5	i 448 450	ZV
T6	i 604 606	ZV
T7	i 1103 1105	ZV
T8	i 1304 1311	placebo
T9	i 1407 1409	ZV
T10	i 1467 1469	ZV
T11	i 1500 1507	placebo
T12	i 1623 1625	ZV
T13	i 1714 1716	ZV
T14	o 6 48	Safety , tolerability , and immunogenicity
T15	o 548 576	immunity and safety profiles
T16	o 661 664	was
T17	o 681 830	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay
T18	o 841 860	experiences ( AEs )
T19	o 938 957	vaccine-related AEs
T20	o 969 972	VZV
T21	o 979 1085	ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear cells
T22	o 1293 1296	GMC
T23	o 1361 1377	ELISPOT response
T24	o 1429 1459	geometric mean titers ( GMTs )
T25	o 1567 1599	IFN-? ELISPOT and gpELISA assays
T26	o 1731 1735	safe
T27	o 1769 1777	immunity